Loading...
NPI 1558366526 · Rockville Centre, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Glenn Stoller is a ophthalmology physician provider located in Rockville Centre, New York. This profile covers 24 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Glenn Stoller |
| Address | 2000 N Village Ave |
| City | Rockville Centre |
| State | NY |
| ZIP | 11570 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 16, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.6M |
| Medicaid | $637.1K |
Practice profile and service mix: GLENN STOLLER’s billing mix is consistent with a high‑volume retina-focused ophthalmology practice that performs large numbers of intravitreal injections and in‑office retinal imaging. The Medicare top codes are dominated by anti‑VEGF/novel intravitreal agents (J0178, J2777, J2778) alongside high volumes of injection procedure 67028 and imaging codes 92235, 92134, and 92250, indicating a combined diagnostic + therapeutic retinal service line. These code selections and volumes point to routine, repeated treatment and monitoring of retinal disease rather than a general ophthalmology or surgical subspecialty pattern.
Medicare revenue concentration: The provider’s top 3 Medicare codes account for 69.6% of total Medicare revenue, showing heavy concentration in a few high‑revenue retinal drug claims. J0178 alone represents $2.5M (53.9% of Medicare revenue) and therefore is the single dominant Medicare revenue driver, with J2777 and J2778 providing most of the remaining concentrated share.
Medicaid revenue concentration and payer mix: On Medicaid the top 3 codes account for 85.6% of total Medicaid revenue and J0178 is again the dominant single code at $416K (65.3% of Medicaid revenue). Overall scale favors Medicare—Medicare revenue is $4.6M versus Medicaid $637.1K—so the practice is effectively Medicare‑led in revenue while still operating a meaningful Medicaid volume focused on the same injection and imaging services.
Competitive standing on Medicare anti‑VEGF: The provider ranks high nationally for aflibercept (J0178 rank #105 of 3204, 97th percentile; notably above typical national volume), indicating a major national presence for that therapy. Other intravitreal drugs show mixed standing (J2777 at the 63rd percentile and J2778 at the 79th percentile), which suggests exceptional aflibercept volume relative to peers but more typical volumes for some alternative agents.
Competitive standing on diagnostic imaging and office exams: Several imaging and exam codes are statistical outliers versus national peers—92014 (99th percentile; extreme outlier), 92235 (99th percentile; extreme outlier), 92250 (100th percentile; extreme outlier), and 92134 (97th percentile; extreme outlier). These high percentiles imply the practice is a regional leader in retinal diagnostic services and likely performs a large internal imaging platform workload that supports its injection program.
Statewide Medicaid standing: For Medicaid the largest code J0178 ranks #25 of 101 in‑state (76th percentile; typical, unremarkable volume), and imaging/injection procedure 67028 ranks #45 of 262 (83rd percentile; typical, unremarkable volume). That profile indicates respectable in‑state participation for retina services but not an overwhelmingly dominant Medicaid market share compared with Medicare national standing.
Operational implications and drug mix: The asymmetry between high aflibercept billing (J0178 dominant in both payers) and low bevacizumab Medicaid rank (J9035 rank #136 of 146 in‑state, 4th percentile) suggests clinical or procurement choices that favor branded anti‑VEGF agents over off‑label/bevacizumab in this practice. High volumes of procedure 67028 and frequent use of imaging codes imply integrated, in‑office treatment pathways that combine same‑site injection and diagnostics.
Tenure and stability: The provider’s NPI was enumerated 2005‑06‑16 (~21 years ago), indicating long clinical tenure and likely established referral relationships and operational workflows that align with the concentrated, high‑volume retinal treatment and imaging pattern seen in both Medicare and Medicaid billing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,550 | $690 | $2.5M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 13,920 | $30 | $403.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,710 | $180 | $309.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,380 | $110 | $269.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,870 | $110 | $198.4K |
| J3490 | Unclassified drugs | 100 | $1,770 | $183.9K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 1,200 | $130 | $150.8K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 870 | $120 | $104.4K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 570 | $160 | $90.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,340 | $40 | $84.2K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
24 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 10 | 230 | 560 | $690 | $693K |
| J2777 | 31 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 5 | 70 | 510 | $180 | $131.6K |
| J2781 | 9 | 40 | 520 | $120 | $75.1K |
| 67028 | 8 | 300 | 400 | $100 | $65.9K |
| J3490 | 32 | 120 | 60 | $470 | $50.8K |
| J7312 | 2 | 20 | 270 | $160 | $48K |
| 67210 | 8 | 40 | 40 | $430 | $46.9K |
| 92242 | 14 | 20 | 110 | $240 | $33K |
| 92014 | 19 | 2,220 | 160 | $100 | $29.3K |
Showing 1–10 of 24
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 780 | $530 | $416K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,860 | $40 | $79.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,420 | $40 | $49.7K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 1,080 | $30 | $36.7K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,480 | $20 | $29.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,860 | $10 | $20.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 80 | $30 | $2.2K |
| 92226 | N/A | 130 | $10 | $1.8K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 30 | $20 | $530 |
| J9035 | Injection, bevacizumab, 10 mg | 10 | $40 | $500 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 25 | 100 | 280 | $650 | $369.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 11,185 | 16,550 | 220 | $90 | $186.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 608 | 2,440 | 330 | $70 | $92.6K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 1,274 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 45 | 260 | 420 | $70 | $65.6K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 345 | 1,490 | 340 | $40 | $48.7K |
| J9035 | Injection, bevacizumab, 10 mg | 136 | 150 | 170 | $80 | $36.7K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 18 | 100 | 150 | $60 | $32.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 148 | 730 | 370 | $20 | $30K |
| 92226 | N/A | 263 | 400 | 270 | $20 | $12.6K |
Other providers in the same ZIP code as Glenn Stoller, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| North Shore Lij, Urgent Care, P.C. | NY | Urgent Care Clinic/Center | $0 | $111.7M |
| Mercy Medical Center | NY | General Acute Care Hospital | $0 | $43.9M |
| Better Home Health Care Agency, Inc. | NY | Home Health Agency | $0 | $22.3M |
| Emmanouil Vasilakis | NY | Orthopedic Physical Therapist | $648.6K | $4.3M |
| Angelito Tan | NY | Neurology Physician | $1.4M | $675.6K |
| Jeff Kopelman | NY | Plastic Surgery within the Head & Neck (Otolaryngology) Physician | $287.1K | $1.1M |
| Todd Halper | NY | Family Medicine Physician | $1.1M | $196.6K |
| Charles Mitgang | NY | Internal Medicine Physician | $1M | $3K |
| Khawaja Hassan | NY | Plastic Surgery Physician | $1M | $0 |
| Farid Shahkoohi | NY | Internal Medicine Physician | $840.4K | $5.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.